As a novel adjunctive medication for the treatment of Parkinson's disease, Ongentys (opicapone) has been widely used in clinical practice in recent years.

How Effective is Ongentys (Opicapone) in Treatment?

Improving Fluctuations in Motor Symptoms

Opicapone inhibits the activity of the COMT enzyme, reducing the metabolism of levodopa and thereby prolonging its duration of action.

Clinical studies have shown that this medication can effectively reduce the "off" time and increase the "on" time in patients with Parkinson's disease, improving fluctuations in motor symptoms.

Enhancing Quality of Life

By stabilizing the plasma concentration of levodopa, opicapone helps patients achieve more sustained symptom control and reduces fluctuations in motor symptoms, thereby improving patients' ability to perform activities of daily living and their overall quality of life.

Long-Term Treatment Benefits

Opicapone’s once-daily dosing regimen is simple and easy to follow, leading to high patient compliance, making it suitable for long-term use.

Populations for Which Ongentys (Opicapone) is Indicated

Primary Indications

Ongentys is indicated for patients with Parkinson's disease who are receiving levodopa/carbidopa treatment but experience "off" episodes.

Such patients typically exhibit fluctuations in drug efficacy, i.e., obvious "on-off" phenomena.

Precautions for Special Populations

Patients with hepatic impairment: Dose adjustment is required for patients with moderate hepatic impairment, and use should be avoided in patients with severe hepatic impairment.

Patients with renal impairment: No dose adjustment is needed for patients with mild to moderate renal impairment, but use should be avoided in patients with end-stage renal disease.

Elderly patients: No dose adjustment is required, but close monitoring for adverse reactions is necessary.

Pregnant and lactating women: Based on animal data, opicapone may cause harm to the fetus; therefore, a careful assessment of the risk-benefit ratio is required.

Contraindicated Populations

Patients concurrently using non-selective monoamine oxidase inhibitors (MAOIs).

Patients with a history of pheochromocytoma, paraganglioma, or other catecholamine-secreting tumors.

Medication Monitoring for Ongentys (Opicapone)

Routine Monitoring Items

Cardiovascular function: Regularly monitor changes in heart rate and blood pressure.

Psychiatric symptoms: Observe for the occurrence of hallucinations and psychotic symptoms.

Motor symptoms: Assess whether dyskinesia has worsened.

Weight changes: Measure body weight regularly.

Adverse Reaction Monitoring

Cardiovascular effects: Arrhythmias, increased heart rate, and excessive changes in blood pressure may occur.

Daytime somnolence: Evaluate patients' alertness during daily activities.

Hypotension/syncope: Monitor for symptoms of orthostatic hypotension.

Dyskinesia: Observe for the worsening or new onset of dyskinesia.

Impulse control disorders: Inquire about increased impulsive behaviors such as gambling and shopping.

Psychiatric symptoms: Be alert to the occurrence of psychiatric symptoms such as hallucinations and delusions.